X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ORCHID PHARMA LTD PLETHICO PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x -1.1 -0.5 - View Chart
P/BV x 0.0 0.4 4.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ORCHID PHARMA LTD
Sep-13
PLETHICO PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs395194 203.6%   
Low Rs3135 89.4%   
Sales per share (Unadj.) Rs604.4276.5 218.6%  
Earnings per share (Unadj.) Rs32.5-79.2 -41.0%  
Cash flow per share (Unadj.) Rs51.3-43.5 -118.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.653.9 878.0%  
Shares outstanding (eoy) m34.0870.45 48.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.40.4 85.1%   
Avg P/E ratio x6.6-1.4 -453.9%  
P/CF ratio (eoy) x4.2-2.6 -157.6%  
Price / Book Value ratio x0.52.1 21.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2628,067 90.0%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m1,5962,527 63.2%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m20,59819,477 105.8%  
Other income Rs m386407 94.9%   
Total revenues Rs m20,98419,884 105.5%   
Gross profit Rs m2,8181,103 255.5%  
Depreciation Rs m6422,519 25.5%   
Interest Rs m1,5935,227 30.5%   
Profit before tax Rs m969-6,236 -15.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m-138-125 110.5%   
Profit after tax Rs m1,107-5,580 -19.8%  
Gross profit margin %13.75.7 241.6%  
Effective tax rate %-14.32.0 -711.7%   
Net profit margin %5.4-28.7 -18.8%  
BALANCE SHEET DATA
Current assets Rs m18,87711,014 171.4%   
Current liabilities Rs m11,89632,060 37.1%   
Net working cap to sales %33.9-108.1 -31.4%  
Current ratio x1.60.3 461.9%  
Inventory Days Days3695 37.9%  
Debtors Days Days19834 589.5%  
Net fixed assets Rs m9,86129,440 33.5%   
Share capital Rs m341705 48.4%   
"Free" reserves Rs m12,3312,043 603.7%   
Net worth Rs m16,1393,800 424.7%   
Long term debt Rs m4,7069,018 52.2%   
Total assets Rs m33,14646,510 71.3%  
Interest coverage x1.6-0.2 -832.6%   
Debt to equity ratio x0.32.4 12.3%  
Sales to assets ratio x0.60.4 148.4%   
Return on assets %8.1-0.8 -1,071.8%  
Return on equity %6.9-146.9 -4.7%  
Return on capital %12.3-3.7 -329.1%  
Exports to sales %21.437.9 56.4%   
Imports to sales %15.222.6 67.3%   
Exports (fob) Rs m4,4027,378 59.7%   
Imports (cif) Rs m3,1364,406 71.2%   
Fx inflow Rs m4,4027,513 58.6%   
Fx outflow Rs m3,1845,649 56.4%   
Net fx Rs m1,2191,865 65.4%   
CASH FLOW
From Operations Rs m2,4371,682 144.9%  
From Investments Rs m-6,265-9,860 63.5%  
From Financial Activity Rs m2,4906,644 37.5%  
Net Cashflow Rs m-1,337-1,535 87.1%  

Share Holding

Indian Promoters % 82.7 32.3 256.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 4.6 93.5%  
FIIs % 5.5 3.3 166.7%  
ADR/GDR % 0.0 4.6 -  
Free float % 7.5 55.3 13.6%  
Shareholders   10,665 84,811 12.6%  
Pledged promoter(s) holding % 85.7 54.9 156.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - DR. REDDYS LAB COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS